KPV (α-MSH 11–13): The Tripeptide That Works Without Its Receptor
Most peptide research programs start from a receptor. A molecule binds a target, the target signals, and the downstream biology follows from that first contact. KPV — the C-terminal tripeptide of α-melanocyte-stimulating hormone, Lys-Pro-Val — is interesting to investigators precisely because it appears to break that chain. It reproduces a substantial part of α-MSH’s anti-inflammatory profile in preclinical systems while showing no measurable affinity for the melanocortin-1 receptor that α-MSH itself uses.
That single anomaly is what makes KPV a useful tool compound rather than a curiosity, and it is the reason this three-residue sequence keeps reappearing in mucosal immunology, dermatology and innate-defense literature more than two decades after it was first characterized. For US laboratories building out an inflammation-signaling panel, it is one of the least expensive entries in the catalog and one of the most mechanistically distinct.
The parent molecule and the fragment
α-MSH is a 13-residue product of pro-opiomelanocortin (SYSMEHFRWGKPV). Its anti-inflammatory activity has been described across a broad set of models, and Brzoska and colleagues assembled the field’s reference synthesis of that work in Endocrine Reviews in 2008 (PMID 18612139), covering α-MSH and its related tripeptides across in vitro and in vivo systems. KPV is simply residues 11–13 of that parent sequence — the last three amino acids, cleaved free.
A reasonable prior would be that a three-residue fragment is a weak partial agonist at the same receptor. The data do not support that prior, and the study that established it is worth reading in the original.
The receptor result: activity without binding
Mandrika and colleagues, publishing in Biochemical Pharmacology in 2001 (PMID 11239505), compared α-MSH, α-MSH(1–10) and α-MSH(11–13) in RAW 264.7 macrophage-like cells stimulated with bacterial lipopolysaccharide and interferon-γ. All three peptides suppressed nitric oxide production, with a potency order of α-MSH ≥ α-MSH(11–13) > α-MSH(1–10). All three inhibited NF-κB nuclear translocation, with α-MSH and the KPV fragment showing maximal effect across a 1 nM–1 µM range.
Then the dissociation. Using ¹²⁵I-labeled NDP-MSH radioligand binding, the investigators demonstrated MC1 receptor binding sites on RAW 264.7 cells. α-MSH and α-MSH(1–10) competed for those sites. α-MSH(11–13) did not compete — not at 1 µM, not at concentrations up to 1 mM. Nor did the tripeptide raise cyclic AMP, while the parent peptide and the 1–10 fragment both produced strong cAMP stimulation. Forskolin, meanwhile, raised cAMP and suppressed nitric oxide output but did not alter NF-κB translocation at all.
The interpretation the data force is that KPV’s suppression of NF-κB translocation in this system is not routed through MC1R and is not routed through the canonical cAMP/PKA arm. Whatever the tripeptide is doing, it is doing intracellularly and by a different mechanism from the molecule it was cleaved from.
Genetic confirmation in a whole-animal model
Cell-line pharmacology is suggestive; a receptor knockout is harder to argue with. Kannengiesser and colleagues, in Inflammatory Bowel Disease in 2008 (PMID 18092346), examined KPV in two established murine colitis models — dextran sodium sulfate (DSS) colitis and CD45RB-high transfer colitis — and then repeated the DSS work in MC1Re/e animals, which express a non-functional melanocortin-1 receptor.
In wild-type DSS colitis, KPV-treated animals recovered earlier and regained significantly more body weight, with histologically reduced inflammatory infiltrates and significantly lower colonic myeloperoxidase activity. The transfer-colitis arm reproduced the pattern. Most relevant to the mechanistic question: in MC1Re/e animals, KPV rescued every animal in the treatment group from mortality during DSS colitis. A peptide acting through MC1R should not do that in animals whose MC1R does not work.
How a tripeptide gets inside a cell
If the mechanism is intracellular, transport becomes the central question. Dalmasso and colleagues addressed it directly in Gastroenterology in 2008 (PMID 18061177), and the answer is PepT1 — the di/tripeptide transporter normally expressed in small intestine and induced in colonic tissue during inflammatory bowel disease.
Working in Caco2-BBE and HT29-Cl.19A human intestinal epithelial lines and in Jurkat human T cells, the group showed that nanomolar KPV concentrations inhibited NF-κB and MAP kinase inflammatory signaling and reduced pro-inflammatory cytokine secretion. Uptake experiments using cold KPV as a competitor for a radiolabeled PepT1 substrate, and separately using [³H]KPV to derive uptake kinetics, established that the peptide enters through PepT1 in both epithelial and immune cells. Orally administered KPV in drinking water reduced the incidence of both DSS- and TNBS-induced colitis in mice.
The transporter finding is the practical hinge of the whole KPV literature. It explains oral activity in rodents for a molecule that would otherwise be expected to be degraded, and it makes PepT1 expression a variable that any in vitro model system has to account for. A cell line that does not express PepT1 is not a fair test of KPV.
Innate defense and viral transcription
Two further lines are worth knowing because they complicate the simple “anti-inflammatory peptide” label. Cutuli and colleagues, in the Journal of Leukocyte Biology in 2000 (PMID 10670585), reported that α-MSH peptides including the 11–13 tripeptide inhibited Staphylococcus aureus colony formation and reduced viability and germ-tube formation in Candida albicans, with effects observed across a broad concentration range extending into the picomolar. Notably, the peptides did not impair neutrophil killing of either organism — they enhanced it.
In the same journal later that year, Barcellini and colleagues (PMID 11073109) reported that α-MSH and KPV reduced p24 antigen release from TNF-α-stimulated, chronically HIV-1-infected promonocytic U1 cells, and that KPV reduced viral replication in acutely infected monocyte-derived macrophages. The mechanism they attribute it to is transcriptional — KPV inhibited the NF-κB activation that drives viral expression. That is the same molecular endpoint as the Mandrika and Dalmasso work, reached from a completely different experimental direction.
Formulation work
Because KPV is small, soluble and rapidly cleared, delivery has attracted its own literature. Xiao and colleagues, in Molecular Therapy in 2017 (PMID 28143741), loaded KPV into hyaluronic acid-functionalized polymeric nanoparticles (~272 nm, ζ ≈ −5.3 mV) and encapsulated those in a chitosan/alginate hydrogel for oral delivery in a mouse ulcerative colitis model. The HA-functionalized construct outperformed the non-functionalized nanoparticle system on mucosal damage and TNF-α downregulation.
For a laboratory characterizing formulation variables, that paper is a useful template: it holds the peptide constant and varies only the carrier, which is the correct design for isolating a delivery effect from a pharmacological one.
What the literature does not establish
Stress-testing the case matters more than restating it. Several things remain open.
The mechanism is still negatively defined. We know KPV suppresses NF-κB translocation, and we know it is not doing so via MC1R binding or cAMP elevation. The positive identity of its intracellular target has not been settled. Papers that describe KPV as an “MC1R agonist” are not consistent with the binding data.
The in vivo work is concentrated in rodent colitis. DSS and TNBS colitis are chemically induced models with well-known limitations as representations of human disease, and results in them routinely fail to generalize. The transfer-colitis and MC1Re/e arms strengthen the mechanistic argument but do not broaden the disease relevance.
Concentration ranges vary enormously across papers — picomolar in the antimicrobial work, nanomolar in the epithelial transport work, up to millimolar in the negative binding controls. Comparing potency across these studies without accounting for system, readout and exposure time is a common error in secondary summaries of this literature.
Characterization notes for US laboratories
KPV’s small size makes analytical verification straightforward but not optional. At 342 Da, the tripeptide sits well within routine LC-MS confirmation range, and RP-HPLC purity determination is uncomplicated relative to longer sequences. Two variables deserve attention: residual TFA from purification, which can carry into cell-based assays at concentrations that affect viability, and net peptide content, which for a molecule this small can diverge meaningfully from chromatographic purity. Both should appear on the batch certificate of analysis.
Every lot we ship carries its own batch COA rather than a representative document, which matters when a published protocol specifies a concentration and the actual peptide content of the vial determines whether the working solution matches it. Laboratories sourcing KPV 10mg, shipped from our Santa Barbara facility, get same-day dispatch on orders placed before cutoff and domestic transit times measured in days rather than the multi-week customs exposure that offshore sourcing introduces — a material consideration for a peptide stored lyophilized but reconstituted on a schedule the experiment sets.
Maple Research Labs is a US entity supplying US laboratories, which removes the import documentation and cross-border delay that fragment procurement timelines and complicate chain of custody records.
All products supplied by Maple Research Labs are for research use only. These materials are not for human use, not for veterinary use, and not for diagnostic or therapeutic application. All findings described above derive from published in vitro and animal-model studies. Nothing in this article describes or implies administration to humans.